Product Images Jakafi

This is a prescription drug named Ruxolitinib phosphate manufactured by Incyte Corporation. It comes in a pack of 60 tablets, each containing 26.4 mg of the drug. The drug is intended for oral intake and is stored in a container at room temperature not exceeding 25°C. The prescribed dosage should only be taken as per the advice provided in the prescribing information.*

Incyte Corporation manufactures and distributes Jakafi tablets (Ruxolitinib). The tablets are available in a pack of 60 and contain ruxolitinib phosphate equivalent to 25mg ruxolitinib free base. The company advises that Jakafi should be stored in a tight container at room temperature (20°C-25°C or 68°F-77°F). Excursions between 15°C and 30°C (59°F and 86°F) are permitted. Jakafi tablets should be protected from light. For usual dosage and other information, the prescribing information should be consulted.*

The text describes a figure labeled "Figure 2" which shows the percent change from baseline in total symptom score for each patient in Study 1. The data is presented as a comparison between patients who were given a placebo (represented by "N=t45") and those who were given some other treatment (not mentioned in the text). The figure also notes that "worsening of total symptom score" is truncated at 150%, although the reason for this truncation is not explained.*

This is a graph showing the percentage of myelofibrosis patients who achieved a 50% or greater reduction in individual symptom scores at week 24. The graph compares the results of patients treated with Jakafi versus those treated with a placebo. The individual symptom scores are in the range of 0 to 10 and include symptoms such as abdominal pain, early satiety, night sweats and itching, bone or muscle pain. Baseline mean and median scores are also provided for each symptom.*

This text describes a figure illustrating the overall survival rates of two treatment groups (Jaan and Best Available Therapy) in Study 2. The x-axis represents time in months, and the y-axis represents survival probability. The figure includes a Kaplan-Meier curve for each treatment group. The number at risk is also provided.*

This is a label of medication manufactured by Incyte Corporation. The medication comes in a container with 60 tablets, and has the NDC (National Drug Code) 50881-005-60. The usual dosage is not provided, but it is recommended to refer to the prescription information. The medication is called ruxolitinib and each tablet contains 6.6 mq ruxolitinib phosphate, equivalent to 5 mg ruxolitinib free base. The medication should be stored in a tight container at room temperature with excursions between 15°C and 30°C allowed. The medication requires protection from light.*

This is a medication description for a product manufactured by Incyte Corporation. The product is a container of 60 tablets, each containing 13.2 mg of ruxolitinib phosphate, which is equivalent to 10 mg of ruxolitinib free base. The usual dosage is not specified, but the prescription information should be consulted. The medication should be stored in a tight container at room temperature, with excursions between 15-30°C permitted. The medication should be protected from light.*

Jakafi is a medication produced by Incyte Corporation for treating certain types of cancers. The usual dosage is detailed in the prescribing information, and it is recommended to keep the tablets in a tightly sealed container away from light at room temperature between 20°C to 25°C with excursions allowed between 15°C to 30°C. Each tablet contains 19.8 mg ruxolitinib phosphate equivalent to 15 mg ruxolitinib free base.*